Endo Pharma Outlook POSITIVE and 4 Stock Analyses Driving the Market

VIVUS Inc. (NASDAQ:VVUS):  Jefferies views the FDA’s decision on VIVUS’s weight loss drug, Qnexa, as a 50-50 outcome, but believes that the current price of shares reflects strong optimism for approval. The firm keeps an Underperform rating on the stock with a $9 price target.

Don’t Miss: Is This Facebook-CRUSHED Rival Back in the Game?

Darden Restaurants, Inc. (NYSE:DRI):  Jefferies believes that  Darden Restaurants, Inc., are a  high-quality growth concept in Yard House, but says that shares will likely become lower in the near-term earnings dilution.  However, he feels that this acquisition makes Darden more attractive looking over the long-term. There is a Buy rating on the stock.

Endo Pharmaceuticals Holdings Inc. (NASDAQ:ENDP): Over the longer term, and in spite of what RBC Capital sees as a lackluster performance by Endo’s tamper resistant formulation of Opana, the firm believes that their product will continue to show significant growth. They recommend buying the stock in the near-term.

VMware, Inc. (NYSE:VMW):  Heading into the second quarter report with reduced expectations, Morgan Stanley views VMware’s risk/reward as attractive. The firm believes that an inline report, or better will drive shares, which are Overweight rated, back to the $90′s.

Green Mountain Coffee Roasters Inc. (NASDAQ:GMCR): Citing increased competition, Stifel Nicolaus slashed Green Mountain’s FY13 earnings per share estimates from $2.27 to $1.80. The firm expects to lose shares and have reduced their fair value stock to $14, while still maintaining a Sell rating.

Don’t Miss: Is Google Leaving Apple in its DUST?

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.